<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">20181974</PMID>
      <DateCompleted>
        <Year>2010</Year>
        <Month>03</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>362</Volume>
            <Issue>8</Issue>
            <PubDate>
              <Year>2010</Year>
              <Month>Feb</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Graves' ophthalmopathy.</ArticleTitle>
        <Pagination>
          <StartPage>726</StartPage>
          <EndPage>738</EndPage>
          <MedlinePgn>726-38</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMra0905750</ELocationID>
        <Abstract>
          <AbstractText>Graves’ ophthalmopathy, also called Graves’ orbitopathy, is a potentially sight-threatening ocular disease that has puzzled physicians and scientists for nearly two centuries.<sup>–</sup> Generally occurring in patients with hyperthyroidism or a history of hyperthyroidism due to Graves’ disease, Graves’ ophthalmopathy is also known as thyroid-associated ophthalmopathy or thyroid eye disease, because it sometimes occurs in patients with euthyroid or hypothyroid chronic autoimmune thyroiditis. The condition has an annual adjusted incidence rate of 16 women and 3 men per 100,000 population. This review explores the perplexing relationship between Graves’ ophthalmopathy, hyperthyroidism, and thyroid dermopathy, the associated skin condition. I examine clinical features, histologic findings, and laboratory studies, with an emphasis on mechanisms that could be targeted in the development of new treatments for this debilitating disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bahn</LastName>
            <ForeName>Rebecca S</ForeName>
            <Initials>RS</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN 55905, USA. bahn.rebecca@mayo.edu</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 DK077814</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R56 DK077814</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>DK77814</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013956">Antithyroid Agents</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D013956" MajorTopicYN="N">Antithyroid Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="N">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006980" MajorTopicYN="N">Hyperthyroidism</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013967" MajorTopicYN="N">Thyroiditis, Autoimmune</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2010</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">20181974</ArticleId>
        <ArticleId IdType="mid">NIHMS377567</ArticleId>
        <ArticleId IdType="pmc">PMC3902010</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMra0905750</ArticleId>
        <ArticleId IdType="pii">362/8/726</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Graves R. Newly observed affection of the thyroid: clinical lectures. Lond Med Surg J. 1835;7:516–7.</Citation>
        </Reference>
        <Reference>
          <Citation>Parry C. Diseases of the heart. Elements Pathol Ther. 1825;2:111–28.</Citation>
        </Reference>
        <Reference>
          <Citation>von Basedow K. Exophthalmos durch hypertrophie des zellgewebes in der augenhöhle. Wochenschr Heilkunde. 1840;6:197–204.</Citation>
        </Reference>
        <Reference>
          <Citation>Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1298522</ArticleId>
            <ArticleId IdType="pubmed">7886878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves’ ophthalmopathy and onset of thyroidal Graves’ disease. J Endocrinol Invest. 1988;11:615–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2907524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12:855–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12487767</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Enzmann DR, Donaldson SS, Kriss JP. Appearance of Graves’ disease on orbital computed tomography. J Comput Assist Tomogr. 1979;3:815–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">583152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wiersinga WM, Smit T, van der Gaag R, Mourits M, Koornneef L. Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res. 1989;21:73–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2786616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol. 2005;6:295–309.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16252929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapoport B, McLachlan SM. The thyrotropin receptor in Graves’ disease. Thyroid. 2007;17:911–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17822379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo DH, Eng PH, Ho SC, et al.  Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10:1093–100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11201855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein AK, Lösch C, Glowacka D, et al.  Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy. Br J Ophthalmol. 2009;93:1052–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19221109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2000;52:267–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10718823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein AK, Plicht M, Lax H, et al.  Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16835285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morris JC, III, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc. 1988;63:707–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2898572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA. 1993;269:479–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8419666</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10782363</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15:737–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17153844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92:59–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17047020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329:1468–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8413459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otto AJ, Koornneef L, Mourits MP, Deen-van Leeuwen L. Retrobulbar pressures measured during surgical decompression of the orbit. Br J Ophthalmol. 1996;80:1042–5. Erratum, Br J Ophthalmol 1997;81:175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC505699</ArticleId>
            <ArticleId IdType="pubmed">9059266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM, Earnest F., IV Ophthalmopathy of Graves’ disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol. 1986;7:651–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3088943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20:568–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2779967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves’ disease. Thyroid. 2000;10:685–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11014313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan LL, Tan HE, Fook-Chong S, Teo TH, Lim LH, Seah LL. Graves ophthalmopathy: the bony orbit in optic neuropathy, its apical angular capacity, and impact on prediction of risk. AJNR Am J Neuroradiol. 2009;30:597–602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7051464</ArticleId>
            <ArticleId IdType="pubmed">19147718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kroll AJ, Kuwabara T. Dysthyroid ocular myopathy: anatomy, histology, and electron microscopy. Arch Ophthalmol. 1966;76:244–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">5945177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev. 1989;10:366–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2673756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riley FC. Orbital pathology in Graves’ disease. Mayo Clin Proc. 1972;47:975–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Pappa A, Calder V, Ajjan R, et al.  Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO) Clin Exp Immunol. 1997;109:362–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1904732</ArticleId>
            <ArticleId IdType="pubmed">9276534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eckstein AK, Quadbeck B, Tews S, et al.  Thyroid associated ophthalmopathy: evidence for CD4(+) γδ T cells, de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells, and loss of γδ and αβ T cell receptor expression. Br J Ophthalmol. 2004;88:803–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1772193</ArticleId>
            <ArticleId IdType="pubmed">15148216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10690890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2003;88:4246–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12970294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85:1194–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10720061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24:802–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14671007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn RS. Clinical review 157: pathophysiology of Graves’ ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88:1939–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12727937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otto EA, Ochs K, Hansen C, Wall JR, Kahaly GJ. Orbital tissue-derived T lymphocytes from patients with Graves’ ophthalmopathy recognize autologous orbital antigens. J Clin Endocrinol Metab. 1996;81:3045–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8768872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorisky A, Pardasani D, Gagnon A, Smith TJ. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab. 1996;81:3428–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8784110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valyasevi RW, Erickson DZ, Harteneck DA, et al.  Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999;84:2557–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10404836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol. 2003;30:369–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12790806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rootman J.  Pathophysiologic patterns of orbital disease. In: Rootman J, editor. Diseases of the orbit: a multidisciplinary approach. 2. Philadelphia: Lippincott Williams &amp; Wilkins; 2003. pp. 43–51.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Tsai CC, Shih MJ, et al.  Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008;18:983–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2574420</ArticleId>
            <ArticleId IdType="pubmed">18788919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao HJ, Han R, Smith TJ. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol. 2003;284:C1429–C1437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12519748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ. The putative role of prostaglandin endoperoxide H synthase-2 in the pathogenesis of thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):S160–S163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10614912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS. Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves’ ophthalmopathy. Thyroid. 2008;18:1291–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2857447</ArticleId>
            <ArticleId IdType="pubmed">18976167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol. 2003;163:1291–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868289</ArticleId>
            <ArticleId IdType="pubmed">14507638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Koumas L, Gagnon A, et al.  Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87:385–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11788681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobyns BM. Present concepts of the pathologic physiology of exophthalmos. J Clin Endocrinol Metab. 1950;10:1202–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14794748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mullin BR, Lee G, Ledley FD, Winland RJ, Kohn LD. Thyrotropin interactions with human fat cell membrane preparations and the finding of soluble thyrotropin binding component. Biochem Biophys Res Commun. 1976;69:55–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">177020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies TF, Teng CS, McLachlan SM, Smith BR, Hall R. Thyrotropin receptors in adipose tissue, retro-orbital tissue and lymphocytes. Mol Cell Endocrinol. 1978;9:303–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">203502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parmentier M, Libert F, Maenhaut C, et al.  Molecular cloning of the thyrotropin receptor. Science. 1989;246:1620–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2556796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagayama Y, Kaufman KD, Seto P, Rapoport B. Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. Biochem Biophys Res Commun. 1989;165:1184–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2558651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid. 1993;3:297–300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7509671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mengistu M, Lukes YG, Nagy EV, et al.  TSH receptor gene expression in retroocular fibroblasts. J Endocrinol Invest. 1994;17:437–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7523481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab. 1997;82:2003–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9177421</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves’ disease retro-orbital tissue. Lancet. 1993;342:337–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8101586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves’ orbital adipose/connective tissues: potential autoantigen in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1998;83:998–1002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9506762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin Endocrinol (Oxf) 2003;58:280–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12608932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Endo T, Ohno M, Kotani S, Gunji K, Onaya T. Thyrotropin receptor in nonthyroid tissues. Biochem Biophys Res Commun. 1993;190:774–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8439328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid. 1997;7:879–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9459631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paschke R, Metcalfe A, Alcalde L, Vassart G, Weetman A, Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab. 1994;79:1234–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7962314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daumerie C, Ludgate M, Costagliola S, Many MC. Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy. Eur J Endocrinol. 2002;146:35–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11751064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McLachlan SM, Nagayama Y, Rapoport B. Insight into Graves’ hyperthyroidism from animal models. Endocr Rev. 2005;26:800–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15827111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker G, Mazziotti G, von Ruhland C, Ludgate M. Reevaluating thyrotropin receptor-induced mouse models of Graves’ disease and ophthalmopathy. Endocrinology. 2005;146:835–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15542454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bednarczuk T, Gopinath B, Ploski R, Wall JR. Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol (Oxf) 2007;67:3–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17521325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol. 2006;7:885–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17139329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lantz M, Vondrichova T, Parikh H, et al.  Overexpression of immediate early genes in active Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2005;90:4784–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15928252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar S, Leontovich A, Coenen MJ, Bahn RS. Gene expression profiling of orbital adipose tissue from patients with Graves’ ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab. 2005;90:4730–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1236982</ArticleId>
            <ArticleId IdType="pubmed">15886250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002;87:2352–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11994387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Starkey K, Heufelder A, Baker G, et al.  Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab. 2003;88:55–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12519830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B. Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol (Oxf) 2006;65:35–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16817816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxydelta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 1995;83:803–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8521497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Konuk EB, Konuk O, Misirlioglu M, Menevse A, Unal M. Expression of cyclo-oxygenase-2 in orbital fibroadipose connective tissues of Graves’ ophthalmopathy patients. Eur J Endocrinol. 2006;155:681–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17062883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldon SE, O’Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol. 2006;169:1183–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1698858</ArticleId>
            <ArticleId IdType="pubmed">17003477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu M, Lin RY. TSH stimulates adipogenesis in mouse embryonic stem cells. J Endocrinol. 2008;196:159–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2692893</ArticleId>
            <ArticleId IdType="pubmed">18180327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci. 2006;47:5197–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1892592</ArticleId>
            <ArticleId IdType="pubmed">17122103</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, Bowen T, Grennan-Jones F, et al.  Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem. 2009;284:26447–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2785333</ArticleId>
            <ArticleId IdType="pubmed">19633293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves’ disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity. 2003;36:409–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14669949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170:6348–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12794168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Hoa N. Immunoglobulins from patients with Graves’ disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15472208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsui S, Naik V, Hoa N, et al.  Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181:4397–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2775538</ArticleId>
            <ArticleId IdType="pubmed">18768899</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grewal IS, Flavell RA. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996;153:85–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9010720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldon SE, Park DJ, O’Loughlin CW, et al.  Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves’ ophthalmopathy. Invest Ophthalmol Vis Sci. 2005;46:3913–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16249464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sempowski GD, Rozenblit J, Smith TJ, Phipps RP. Human orbital fibroblasts are activated through CD40 to induce pro-inflammatory cytokine production. Am J Physiol. 1998;274:C707–C714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9530102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci. 1992;33:2037–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1582808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995;268:C382–C388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7864077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang HS, Cao HJ, Winn VD, et al.  Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for connective tissue inflammation. J Biol Chem. 1996;271:22718–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8798446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 1986;233:566–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3726549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valyasevi RW, Jyonouchi SC, Dutton CM, Munsakul N, Bahn RS. Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2001;86:903–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11158064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002;2:748–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12360213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature. 2005;435:612–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15931214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004;350:2167–79.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15152062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2:364–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12033742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarello CA. The role of the interleukin-1–receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000;343:732–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10974140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2006;2:619–26. Erratum, Nat Clin Pract Rheumatol 2006;2:691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17075601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005;24:117–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16191800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond) 2005;19:1286–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15550932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36:1118–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19447938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1996;81:449–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8636247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smolen JS, Beaulieu A, Rubbert-Roth A, et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18358926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pohlers D, Brenmoehl J, Löffler I, et al.  TGF-beta and fibrosis in different organs — molecular pathway imprints. Biochim Biophys Acta. 2009;1792:746–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19539753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wertenbruch T, Willenberg HS, Sagert C, et al.  Serum selenium levels in patients with remission and relapse of Graves’ disease. Med Chem. 2007;3:281–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17504200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsokos GC. B cells, be gone — B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med. 2004;350:2546–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15201410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid. 2006;16:709–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16889501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwan-Morley J, Albert D. B-cell inhibitors as therapy for rheumatoid arthritis: an update. Curr Rheumatol Rep. 2007;9:401–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17915096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvi M, Vannucchi G, Campi I, et al.  Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17218723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005;352:2598–608.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15972866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kremer JM, Westhovens R, Leon M, et al.  Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14614165</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalunian KC, Davis JC, Jr, Merrill JT, Totoritis MC, Wofsy D IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12483729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev. 2004;25:899–918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15583022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007;28:551–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17981503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cozma I, Zhang L, Uddin J, Lane C, Rees A, Ludgate M. Modulation of expression of somatostatin receptor subtypes in Graves’ ophthalmopathy orbits: relevance to novel analogs. Am J Physiol Endocrinol Metab. 2007;293:E1630–E1635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17848636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neumann S, Kleinau G, Costanzi S, et al.  A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology. 2008;149:5945–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2613050</ArticleId>
            <ArticleId IdType="pubmed">18669595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003;112:1785–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC297006</ArticleId>
            <ArticleId IdType="pubmed">14679172</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006;6:394–403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16622478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130:252–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18964302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salvi M, Vannucchi G, Campi I, et al.  Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol. 2009;131:360–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19195932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov.  [Accessed January 21, 2010];Trial of rituximab for Graves’ ophthalmopathy.  at  http://clinicaltrials.gov/ct2/show/NCT00595335.</Citation>
        </Reference>
        <Reference>
          <Citation>Misharin AV, Nagayama Y, Aliesky HA, Mizutori Y, Rapoport B, McLachlan SM. Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies. Endocrinology. 2009;150:3944–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2717879</ArticleId>
            <ArticleId IdType="pubmed">19389831</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. 2009;150:519–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2630889</ArticleId>
            <ArticleId IdType="pubmed">18719020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12039694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bartalena L, Baldeschi L, Dickinson AJ, et al.  Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid. 2008;18:333–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18341379</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
